J. Safra Sarasin Holding’s Madrigal Pharmaceuticals MDGL Stock Holding History

J. Safra Sarasin Holding’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.05M	Sell	1,950 -373	-16%	-$191K	0.02%	380
2026 Q1	$1.22M	Buy	2,323 +777	+50%	+$371K	0.02%	262
2025 Q4	$900K	Sell	1,546 -851	-36%	-$435K	0.01%	325
2025 Q3	$1.1M	Sell	2,397 -4,426	-65%	-$1.65M	0.02%	305
2025 Q2	$2.06M	Buy	6,823 +5,031	+281%	+$1.5M	0.04%	214
2025 Q1	$594K	Sell	1,792 -1,613	-47%	-$530K	0.01%	403
2024 Q4	$1.05M	Sell	3,405 -2,195	-39%	-$617K	0.02%	314
2024 Q3	$1.19M	Sell	5,600 -151	-3%	-$38.6K	0.02%	296
2024 Q2	$1.61M	Buy	+5,751	New	+$1.37M	0.03%	252

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

J. Safra Sarasin Holding's MDGL Position: Q2 2026 in Review

J. Safra Sarasin Holding reduced its Madrigal Pharmaceuticals (MDGL) stake by 16% in Q2 2026, selling an estimated $191K and leaving 1,950 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #380.

J. Safra Sarasin Holding first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.06M in Q2 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

J. Safra Sarasin Holding held 1,950 shares of Madrigal Pharmaceuticals worth $1.05M as of Q2 2026.
J. Safra Sarasin Holding sold 373 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $191K.
Madrigal Pharmaceuticals made up 0.02% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #380 holding.
J. Safra Sarasin Holding first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
J. Safra Sarasin Holding's Madrigal Pharmaceuticals position peaked at $2.06M in Q2 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.